This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Before the main event at JP Morgan 2023 even kicks off, we’re checking out the Sachs Associates Neuroscience Innovation Forum on Sunday. Speakers from Lilly, Boehringer Ingelheim, Takeda, and many more pharma firms big and small will present on key trends and developments in one of the most exciting areas of pharmaceutical and digital innovation. We’ll also wander over to the UC Davis Health Future & Health CEO Summit a little later this afternoon.
Day One Biopharmaceuticals said Sunday that a targeted therapy shrank tumors by at least 50% in a majority of children with the most common form of pediatric brain cancer, setting up a potential approval in a rare disease long overlooked by drugmakers. The new data expand on earlier results released last year from 22 patients. Of the 69 pediatric low-grade glioma patients now evaluated, 44, or 64%, saw their tumors dwindle to less than half their original size, including three patients who
An analysis suggests that early emollient use prevents the development of atopic eczema in high-risk infants especially if an emulsion is used. The early prophylactic emollient use (EU) in high-risk infants appears able to prevent the development of atopic eczema (AE) with emollient emulsions likely to be the most effective, according to the findings of a network meta-analysis by Chinese researchers.
Hospitals, health insurers, and other provider-related companies are returning in person to the J.P. Morgan Healthcare Conference for the first time since the coronavirus upended the health care economy. But the more things have changed since then, the more they have stayed the same. Health care gobbled up 18.3% of the U.S. economy by the end of 2021, according to the latest data from federal actuaries.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The Road to Explainable AI in GXP-Regulated Areas Trudy Patterson Sun, 01/08/2023 - 13:23 Features January / February 2023 The Road to Explainable AI in GXP-Regulated Areas Elias Altrabsheh Martin Heitmann, FRM Patrick Steinmüller Bruna Pastori Vinco 1 January 2023 Recent advances in artificial intelligence (AI) have led to its widespread industrial adoption, with machine learning (ML) algorithms demonstrating advances in performance in a wide range of tasks.
SAN FRANCISCO — What should be a triumphant return to the global biotech industry’s biggest annual event, “JPM Week,” after a two-year hiatus is turning as gloomy as Bay Area weather, with industry executives forecasting economic troubles in the year ahead. STAT asked more than 100 biotech and pharma executives, investors, and other insiders how they’re feeling about the state of the sector heading into 2023 and on the eve of the J.P.
For years, BioMarin CEO Jean-Jacques “J.J.” Bienaime has been saying that Roctavian — the company’s gene therapy to treat hemophilia A — could be the biggest product the biotech firm has ever launched. Based on a meeting with STAT Sunday, his hopes don’t seem to have dimmed a bit despite the regulatory delays the product has faced in the U.S.
The ADA has released its 2023 guidelines. There are a significant number of impacts on medication therapy, and in this post I will outline my most important takeaways. I was also recently catching up with my friend and fellow pharmacist, Derek Borkowski who is the founder of pyrls.com and they again would like to share their excellent […]. The post 2023 ADA Guidelines – Free PDF and My 3 Big Takeaways appeared first on Med Ed 101.
In 2023, the pharmaceutical industry will mark 20 years since Xolair, an anti-IgE antibody, became the first biologic approved to treat asthma. Since then, the US FDA, EMA, and other agencies have approved several biologic antibodies targeting the inflammatory cytokines IL-4, IL-13, IL-5, and others for asthma. Approaches like bronchodilator inhalers focus on treating both asthma and chronic obstructive pulmonary disease (COPD).
By Larry K. Houck — In October, when pardoning those federally convicted of cannabis possession, President Joe Biden directed the Secretary of Health and Human Services (“HHS”) and the Attorney General “to initiate the administrative process to review expeditiously how marijuana is scheduled under federal law.” See President Biden Gives the Green Light for Significant Marijuana Reform, October 10, 2022.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Molnupiravir treatment failed to reduce both COVID-related hospitalisation and mortality among high-risk vaccinated adults in the community. Molnupiravir treatment for vaccinated, high-risk patients who become infected with COVID-19, failed to reduce both the rate of hospitalisation and death in comparison to usual care according to the findings of a large, randomised trial by members of the PANORAMIC Trial collaborative group.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
122 
Let's personalize your content